{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:09:59Z","timestamp":1789146599341,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01032-y","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:26:37Z","timestamp":1789143997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Role of CYP3A4 in Determining In Vivo Exposure to Cannabidiol (CBD) and its Active Metabolite 7-OH-CBD: Evidence from an In Vitro Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3808-8995","authenticated-orcid":false,"given":"Nattapon","family":"Jaisupa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Birgersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"3","key":"1032_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. A practical guide to the treatment of Dravet syndrome with anti-seizure medication. CNS Drugs. 2022;36(3):217\u201337. https:\/\/doi.org\/10.1007\/s40263-022-00898-1.","journal-title":"CNS Drugs"},{"issue":"9","key":"1032_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-019-00666-8","volume":"33","author":"EC Wirrell","year":"2019","unstructured":"Wirrell EC, Nabbout R. Recent advances in the drug treatment of Dravet syndrome. CNS Drugs. 2019;33(9):867\u201381. https:\/\/doi.org\/10.1007\/s40263-019-00666-8.","journal-title":"CNS Drugs"},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.seizure.2018.10.016","volume":"63","author":"A Verrotti","year":"2018","unstructured":"Verrotti A, Striano P, Iapadre G, Zagaroli L, Bonanni P, Coppola G, et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure. 2018;63:17\u201325. https:\/\/doi.org\/10.1016\/j.seizure.2018.10.016.","journal-title":"Seizure"},{"issue":"3","key":"1032_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10072-017-3188-y","volume":"39","author":"AA Asadi-Pooya","year":"2018","unstructured":"Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39(3):403\u201314. https:\/\/doi.org\/10.1007\/s10072-017-3188-y.","journal-title":"Neurol Sci"},{"key":"1032_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114237","volume":"359","author":"DS Reddy","year":"2023","unstructured":"Reddy DS. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Exp Neurol. 2023;359:114237. https:\/\/doi.org\/10.1016\/j.expneurol.2022.114237.","journal-title":"Exp Neurol"},{"key":"1032_CR6","doi-asserted-by":"publisher","unstructured":"Contin M, Mohamed S, Santucci M, Lodi MAM, Russo E, Mecarelli O, Cbd Lice Italy Study G. Cannabidiol in pharmacoresistant epilepsy: clinical pharmacokinetic data from an expanded access program. Front Pharmacol. 2021;12:637801. https:\/\/doi.org\/10.3389\/fphar.2021.637801.","DOI":"10.3389\/fphar.2021.637801"},{"key":"1032_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","volume":"95","author":"JP Szaflarski","year":"2019","unstructured":"Szaflarski JP, Hernando K, Bebin EM, Gaston TE, Grayson LE, Ampah SB, et al. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy Behav. 2019;95:131\u20136. https:\/\/doi.org\/10.1016\/j.yebeh.2019.03.042.","journal-title":"Epilepsy Behav."},{"issue":"10","key":"1032_CR8","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1124\/dmd.120.000350","volume":"49","author":"JL Beers","year":"2021","unstructured":"Beers JL, Fu D, Jackson KD. Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol. Drug Metab Dispos. 2021;49(10):882\u201391. https:\/\/doi.org\/10.1124\/dmd.120.000350.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1032_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053\u201367. https:\/\/doi.org\/10.1007\/s40263-018-0578-5.","journal-title":"CNS Drugs"},{"issue":"1","key":"1032_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.9740\/mhc.2015.01.008","volume":"6","author":"M Marvanova","year":"2016","unstructured":"Marvanova M. Pharmacokinetic characteristics of antiepileptic drugs (AEDs). Ment Health Clin. 2016;6(1):8\u201320. https:\/\/doi.org\/10.9740\/mhc.2015.01.008.","journal-title":"Ment Health Clin"},{"issue":"8","key":"1032_CR11","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.2174\/1570159x20666220524121645","volume":"21","author":"G Zaccara","year":"2023","unstructured":"Zaccara G, Franco V. Pharmacokinetic interactions between antiseizure and psychiatric medications. Curr Neuropharmacol. 2023;21(8):1666\u201390. https:\/\/doi.org\/10.2174\/1570159x20666220524121645.","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"1032_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","volume":"52","author":"X Wen","year":"2001","unstructured":"Wen X, Wang JS, Kivist\u00f6 KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52(5):547\u201353. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01474.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1032_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/s0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, Rousseau M, d\u2019Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490\u2013504. https:\/\/doi.org\/10.1016\/s0009-9236(97)90044-8.","journal-title":"Clin Pharmacol Ther"},{"issue":"S1","key":"1032_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","volume":"41","author":"WR Garnett","year":"2000","unstructured":"Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(S1):61\u20135. https:\/\/doi.org\/10.1111\/j.1528-1157.2000.tb02174.x.","journal-title":"Epilepsia"},{"issue":"3","key":"1032_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/00498254.2025.2498696","volume":"55","author":"N Jaisupa","year":"2025","unstructured":"Jaisupa N, Ashton M, Birgersson S. Cannabidiol metabolism in vitro: the role of antiseizure medications and CYP2C19 genotypes. Xenobiotica. 2025;55(3):246\u201355. https:\/\/doi.org\/10.1080\/00498254.2025.2498696.","journal-title":"Xenobiotica"},{"issue":"24","key":"1032_CR16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/17576180.2026.2612921","volume":"17","author":"N Jaisupa","year":"2025","unstructured":"Jaisupa N, Ashton M, Birgersson S. A simple, sensitive and rapid bioanalytical method for quantifying cannabidiol (CBD), 7-OH-CBD and 7-COOH-CBD in human plasma. Bioanalysis. 2025;17(24):1719\u201330. https:\/\/doi.org\/10.1080\/17576180.2026.2612921.","journal-title":"Bioanalysis"},{"key":"1032_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/dddt.S154388","volume":"12","author":"A Reimers","year":"2018","unstructured":"Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther. 2018;12:271\u201380. https:\/\/doi.org\/10.2147\/dddt.S154388.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1032_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/00498254.2022.2128468","volume":"52","author":"A Kerins","year":"2022","unstructured":"Kerins A, Koszyczarek M, Smith C, Butler P, Riley R, Madgula V, et al. The in vitro metabolism and in vivo pharmacokinetics of the bacterial \u03b2-glucuronidase inhibitor UNC10201652. Xenobiotica. 2022;52(8):904\u201315. https:\/\/doi.org\/10.1080\/00498254.2022.2128468.","journal-title":"Xenobiotica"},{"issue":"4","key":"1032_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s12325-024-02813-0","volume":"41","author":"A Bacq","year":"2024","unstructured":"Bacq A, Depaulis A, Castagn\u00e9 V, Le Guern ME, Wirrell EC, Verleye M. An update on stiripentol mechanisms of action: a narrative review. Adv Ther. 2024;41(4):1351\u201371. https:\/\/doi.org\/10.1007\/s12325-024-02813-0.","journal-title":"Adv Ther"},{"issue":"3","key":"1032_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2165\/00003088-199733030-00004","volume":"33","author":"P Glue","year":"1997","unstructured":"Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin Pharmacokinet. 1997;33(3):214\u201324. https:\/\/doi.org\/10.2165\/00003088-199733030-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1032_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","volume":"14","author":"MS Benedetti","year":"2000","unstructured":"Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14(4):301\u201319. https:\/\/doi.org\/10.1111\/j.1472-8206.2000.tb00411.x.","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"1032_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cpdd.665","volume":"8","author":"G Morrison","year":"2019","unstructured":"Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, open-label, pharmacokinetic trial to investigate possible drug\u2013drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(8):1009\u201331. https:\/\/doi.org\/10.1002\/cpdd.665.","journal-title":"Clin Pharmacol Drug Dev."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01032-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:26:39Z","timestamp":1789143999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01032-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":22,"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01032-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}